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Edited by Stuart FergusonAbstract Freshly isolated human monocytes transport L-argi-
nine mostly through a sodium independent, NEM insensitive
pathway inhibited by L-leucine in the presence, but not in the
absence of sodium. Interferon-c (IFNc) stimulates this pathway,
identiﬁable with system yþL, and markedly enhances the
expression of SLC7A7, the gene that encodes for system yþL
subunit y+LAT1, but not of SLC7A6, that codes for the
alternative subunit y+LAT2. System yþ plays a minor role in
arginine uptake by monocytes and the expression of system yþ-
related genes, SLC7A1 and SLC7A2, is not changed by IFNc.
These results demonstrate that system yþL is sensitive to IFNc.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Four distinct mechanisms, named systems yþ, yþL, b0;þ, and
B0;þ, account for the transport of cationic amino acids (CAA)
in mammalian cells (see [1] for review). Among these, system
yþL is an exchange route that recognizes CAA in the absence
of sodium but requires the cation to interact with neutral
amino acids such as leucine [2]. Its activity can be easily dis-
criminated from system yþ due to the sensitivity of the latter to
NEM inhibition [3]. System yþL is a glycoprotein-associated
amino acid heterodimeric transporter, whose heavy chain is
the glycoprotein CD98/4F2hc and the alternative light chains,
y+LAT1 or y+LAT2, are responsible for the recognition and
operational features of the transport process [4]. While the
system has been implied in the trans-epithelial absorption of
CAA [4], its functional role in non-epithelial tissues is still
unclear and deﬁnite examples of regulatory changes of its ac-
tivity have not yet been reported.
In several cell models of monocyte/macrophage lineage, pro-
inﬂammatory compounds, such as LPS and IFNc, stimulate* Corresponding author. Fax: +39-521-903742.
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the induction of the system-yþ-related CAT-2B transporter [5–
9], while no information is available on possible changes in
system yþL activity under the same conditions. However, most
of those studies were performed on murine models and recent
evidence suggests that the regulation of CAA transport in
murine and human monocytes/macrophages may be diﬀerent
[10]. On the other hand, although the expression of system yþL
in human leukocytes has been reported [11,12], it has not been
neither referred to a particular cell type nor studied in cyto-
kine-treated cells.
Here, we demonstrate that system yþL is the main transport
mechanism for arginine in human monocytes and that it is
speciﬁcally upregulated by IFNc through the induction of
SLC7A7/y+LAT1.2. Materials and methods
2.1. Monocyte isolation and culture conditions
Mononuclear cells were separated from buﬀy coats, obtained from
six normal healthy volunteers, supplied by the Unita di Immunoe-
matologia e trasfusione of Azienda Ospedaliera di Parma (Parma). The
buﬀy coats, diluted 1:4 with PBS, were layered on 10 ml of Fycoll
Hypaque and centrifuged at 750· g for 30 min at 20 C. Peripheral
blood mononuclear cells (PBMC) at the interface were removed, wa-
shed three times in PBS, and centrifuged at 150· g for 10 min at 20 C.
After the ﬁnal wash, PMBC were suspended in RPMI containing 2%
endotoxin-free fetal bovine serum (FBS) and seeded on plastic-ware
appropriate for the various determinations. After a 30-min incubation
at 37 C in an atmosphere at 5% CO2, non-adherent cells were re-
moved with three vigorous washes with prewarmed sterile Earle’s
Balanced Salt Solution (EBSS). Adherent monocytes were employed
immediately (for characterization of arginine transport and expression
of CAA transporters in freshly isolated cells) or collected, resuspended
in RPMI supplemented with 10% FBS in the absence or in the presence
of IFNc (10 ng/ml), and maintained at 37 C under gentle agitation for
the indicated times. After the incubation, monocytes were let to sedi-
ment for 1 h before the experimental determinations. The experiments
shown are typical experiments with variability among transport values
not exceeding 30%. To assess the purity of the preparation, cells were
stained with monocyte-speciﬁc anti-CD14 mAb. More than 75% of the
isolated cells express CD14 (not shown).
2.2. L-Arginine inﬂux
For transport studies, cells were seeded on 96-well dishes. Mono-
cytes, washed once with a modiﬁed bicarbonate-free EBSS buﬀered at
pH 7.4 with 20 mM Tris/HCl, were incubated for 1 min in 50 ll of the
same solution containing [3H]-arginine (4 lCi/ml, 100 lM). In this
interval of time, arginine uptake approached linearity (results notblished by Elsevier B.V. All rights reserved.
Fig. 1. Characterization of L-arginine inﬂux in human monocytes.
Upper panel: Freshly isolated monocytes, seeded for 1 h in RPMI
supplemented with 10% FBS, were washed in EBSS or Naþ-free
NMG-EBSS, as indicated. Arginine uptake was then assayed with 1-
min incubations in the same solution employed for washing, supple-
mented with 100 lM L-[3H]arginine in the presence of the indicated
concentrations of L-leucine. (m) Arginine uptake in the presence of 2
mM L-leucine+ 2 mM L-lysine. Where indicated, before the uptake
assay, cells were pre-treated for 2 min with NEM (0.4 mM). Points are
means of four independent determinations with S.D. indicated when
greater than point size. Lines represent the best ﬁt of experimental data
to Eq. (2) (see Section 2). Middle panel: RT-PCR products (35 cycles
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cold PBS and cell monolayers were extracted in 50 ll ethanol. The
radioactivity in cell extracts was determined with Microbeta Trilux
(Wallac). Extracted cells were then dissolved with 0.5% sodium de-
oxycholate in 1 M NaOH and protein content was determined directly
in the well using a modiﬁed Lowry procedure as previously described
[13]. In the experiments in which Naþ-independent transport was to be
measured, a modiﬁed Naþ-free EBSS (NMG-EBSS) was employed. In
this solution NaCl and NaH2PO4 were replaced, respectively, by N -
methyl-D-glucamine and choline salts.
2.3. Expression of inﬂux data
Amino acid inﬂux is expressed as nmoles per mg of protein per
minute. Kinetic parameters of arginine inﬂux were determined by non-
linear regression analysis using the equation:
v ¼ Vmax  ½S
Km þ ½S þ KD  ½S ð1Þ
for a transport process resulting from the additive operations of a
saturable system and a non-saturable component
v ¼ v0  Imax  ½II0:5 þ ½I ð2Þ
for a competitively inhibited system, where v0 is the inﬂux in the ab-
sence of the inhibitor, Imax is the maximal inhibition and I0:5 is the
inhibitor concentration required for half maximal inhibition.
2.4. Reverse transcription and semi-quantitative PCR
For expression studies, monocytes were seeded on 6-well trays.
Isolation of total RNA and reverse transcription were performed as
described previously for endothelial cells [13]. Brieﬂy, 100 ng of single-
stranded cDNA from each sample was ampliﬁed with 1.0 PCR
buﬀer, 0.2 mM each dNTPs, 2.5 mM MgCl2, along with proband
primers and 1.25 U of Hot Master Taq DNA polymerase. Primer se-
quences were reported previously [13]. Number of cycles is detailed for
each experiment. Images of the electrophoresed cDNAs were recorded
with a digital DC 120 Kodak camera and quantiﬁed by ID Image
Analysis Software (Kodak Digital Science). In semi-quantitative ex-
periments, GAPDH primers were also added in the ampliﬁcation
mixture and the results were expressed as the densitrometric ratio of
proband vs. GAPDH product.
2.5. Materials
Endotoxin-free FBS was purchased from Celbio and culture medium
(RPMI 1640) from Cambrex Bio Science. Human recombinant INFc
and CD14 mAb were from Vinci Biochem. [L-2,3,4-3H]Arginine 45–70
Ci/mmol) was obtained from Perkin–Elmer Italia, Hot Master Taq
polymerase from Eppendorf SrL, and Fycoll Hypaque from Amer-
sham Pharmacia Biotech. Sigma was the source of all the other
chemicals.of ampliﬁcation) obtained with the primers of the indicated genes (see
Section 2). The experiment was repeated in cells isolated from three
diﬀerent subjects with comparable results. Lower panel: RT-PCR
products obtained with the same primers employing RNA isolated
from Calu-3 human lung adenocarcinoma cells as positive control. 35
cycles of ampliﬁcation were employed.3. Results
3.1. Characterization of L-arginine transport in human
monocytes
To discriminate the diﬀerent components of CAA uptake in
freshly isolated human monocytes, maintained in control me-
dium (FBS-supplemented RPMI), L-arginine uptake was in-
hibited, in the presence or in the absence of sodium, with
increasing concentrations of L-leucine (Fig. 1, upper panel).
The assay was performed with cells either treated or untreated
with NEM, a well known inhibitor of system yþ but not of
system yþL [3]. In the absence of leucine, the substitution of
extracellular sodium did not inhibit L-arginine uptake, thus
excluding a signiﬁcant contribution of sodium dependent
transport systems, such as B0;þ. Leucine inhibited arginine
transport only in the presence of sodium, a result compatible
with system yþL activity, but excluding a signiﬁcant contri-bution of system b0;þ. The kinetic analysis of inhibition by
leucine indicated that, at an arginine concentration of 100 lM,
the inﬂux of the CAA was leucine-inhibitable by more than
65% with an I0:5 of 0.21 mM. However, if L-leucine was present
at the maximal concentration employed (2 mM), the addition
of 2 mM lysine did not produce any further decrease of argi-
nine transport, thus indicating the complete inhibition of high
aﬃnity arginine inﬂux by leucine. In the absence of sodium,
leucine actually exerted a signiﬁcant cis-stimulation of arginine
inﬂux. Under all conditions, the pre-incubation of monocytes
with NEM (0.4 mM for 2 min) did not inhibit L-arginine up-
take, conﬁrming that system yþ contribution was, at best,
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Eq. (1)) was compatible with the operation of a single satu-
rable system, endowed with a Km of 51.8 9.6 lM and a Vmax
of 1.028 0.17 nmol/mg of protein/min (results not shown).
Fig. 1, middle panel, shows the RT-PCR analysis of CAA
transporters expressed in human monocytes. The expression of
SLC7A1, coding for system yþ transporter CAT1, was clearly
detectable, whereas SLC7A2 expression was less evident and
detected only for the CAT2B transcript. Transcripts encoded
by all the known genes for system yþL were detectable in
human monocytes: SLC3A2, that codes for system yþL heavy
chain CD98/4F2hc, SLC7A7, that codes for the light chain
y+LAT1, and SLC7A6, for the alternative y+LAT2 light
chain.
3.2. Eﬀect of IFNc on L-arginine uptake in human monocytes
To study the eﬀect of IFNc on the discriminated inﬂux of
arginine in human monocytes, cells were maintained in a
complete growth medium in the presence of 10 ng/ml IFNc
for 24 or 48 h (Fig. 2). L-arginine inﬂux was determined either
in the absence of inhibitors or in the presence of 2 mM leu-
cine, to inhibit system yþL transport activity, or of 2 mM
leucine + 2 mM lysine, to inhibit the whole saturable compo-
nent of arginine transport. Therefore, the portion of arginine
transport inhibited by leucine was ascribed to system yþL
activity, while the transport further inhibited by lysine was
considered the contribution of system yþ. After a 24 h-treat-
ment (panel A), IFNc produced a modest, although signiﬁ-
cant, increase of L-arginine transport, that was fully
attributable to an increase of system yþL activity. After 48 h
of treatment (panel B), the stimulation of arginine inﬂux bycontrol
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Fig. 2. Eﬀect of incubation with IFNc on the discriminated transport
of L-arginine in human monocytes. Monocytes were incubated in
RPMI containing 10% FBS in the absence or in the presence of IFNc
(see Section 2) for 24 h (Panel A) or 48 h (Panel B). After this time, L-
arginine uptake assay was performed as described in the legend of Fig.
1. System yþL: Leucine-inhibitable component of arginine inﬂux,
calculated as the diﬀerence between total inﬂux and the inﬂux mea-
sured in the presence of 2 mM leucine. System yþ: the component of
arginine inﬂux, calculated as the diﬀerence between the inﬂux mea-
sured in the presence of 2 mM leucine and the inﬂux measured in the
presence of both 2mM leucine and 2 mM lysine. Bars are means of four
independent determinations with S.D. indicated. The experiment was
repeated in cells isolated from ﬁve diﬀerent donors with comparable
results. *P < 0:05; ***P < 0:001.IFNc was much more evident and, again, fully accounted for
by a marked increase of system yþL transport activity (+290%
compared with control values). Values of arginine transport in
control, untreated cells remained substantially unchanged
throughout the 48-h incubation.
3.3. Eﬀects of IFNc on the expression of CAA transporter genes
in human monocytes
Fig. 3 reports the results of a semi-quantitative RT-PCR
analysis of the expression of genes for CAA transporters in
monocytes treated with IFNc. With the number of cycles
adopted for each proband cDNA, all the proband transcripts
were clearly detectable and their signal was not saturated. The
only gene signiﬁcantly induced by the cytokine was SLC7A7
(top left panel). The densitometric analysis (top right panel)
revealed that, in IFNc-treated monocytes, the relative abun-
dance of SLC7A7 expression, corrected for GAPDH, was in-
creased more than twofold at 24 h and more than threefold at
48 h compared with control, untreated cells. Under the same
conditions, the expression of SLC3A2, the gene for system yþL
heavy chain CD98/4F2hc, and of SLC7A6, the gene for the
alternative light chain y+LAT2, exhibited no signiﬁcant
change (middle panel, left) as demonstrated by the densito-
metric analysis (middle panel, right). Also the RT-PCR
products of system yþ-related genes SLC7A1 and SLC7A2
(CAT2B transcript) were not changed by the treatment with
the cytokine (bottom panels).4. Discussion
Arginine transport in monocytes/macrophages has been
extensively investigated, but most of these studies have em-
ployed rodent cell lines [5–9]. In those models, the contribu-
tion of system yþ to CAA transport has been emphasized due
to the regulatory links that exist between CAT transporters
and nitric oxide production [8]. Much less data are available
for human models. In a preparation of human PBMC (85%
lymphocytes/15% monocytes), comparable contributions of
systems yþ and yþL to CAA transport have been reported
[14]. Moreover, with a similar cell preparation, Reade et al.
[15] attribute only a minor role to system yþ in non-stimu-
lated PBMC, although its activity is increased in septic shock
patients. The present study demonstrates that, while the
contribution of system yþ appears marginal, system yþL is
the major transport system for arginine under basal condi-
tions and its activity is markedly stimulated by IFNc. Since
monocytes are the typical targets of this cytokine, the stim-
ulation of system yþL may be involved in the activation
process induced by IFNc in these cells. It should be stressed
that circulating monocytes are quiescent cells that, once mi-
grated into peripheral tissues, undergo a complex maturation
process to reach full diﬀerentiation and functional compe-
tence. Indeed, the production of nitrites by these cells is very
low and uncorrelated to the stimulation of arginine trans-
port through system yþL by IFNc (B.M. Rotoli, unpublished
results).
The main characteristics shown by system yþL in human
monocytes are similar to those found in human mesenchymal
models [13,16]. At variance with those models, however, hu-
man monocytes exhibit a signiﬁcant stimulation of arginine
transport by extracellular leucine under sodium-free conditions
Fig. 3. Eﬀect of IFNc on the expression of genes related to transporters for CAA in human monocytes. Cells were incubated for the indicated times in
the presence of 10 ng/ml of IFNc before RNA extraction. For the analysis of SLC7A1, SLC7A2/CAT2B, SLC3A2, and SLC7A6, after reverse
transcription the cDNA solution was divided into two aliquots. One, supplemented with GAPDH primers, underwent 25 cycles of ampliﬁcation to
detect GAPDH transcript. The other, supplemented with the proband primers, underwent 35 cycles of ampliﬁcation. The ampliﬁcation products of
GAPDH and the proband transcript, mixed together, were then put on the same gel. For the analysis of SLC7A7, proband and GAPDH primers
were put in the same ampliﬁcation mixture and underwent 32 cycles of co-ampliﬁcation. Left: Images of RT-PCR products. SLC7A7 (upper panel),
SLC3A2 and SLC7A6 (middle panel), SLC7A1 and SLC7A2/CAT2B (lower panel) at the indicated times of incubation in the presence of IFNc.
Right: Densitometric analyses of the gels shown at left. In each panel, the relative intensity of the ampliﬁcation product of the proband cDNA was
normalized to that of the GAPDH product obtained from the ampliﬁcation of the same cDNA mixture. The analysis, repeated in three diﬀerent
monocytes preparations, yielded comparable results.
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arginine inﬂux by leucine entered into the cells through parallel
pathways other than system yþL during the transport assay.
This explanation would require conditions, such as an out-
wardly directed sodium gradient and a low intracellular amino
acid pool, that may actually occur in the experimental setting
adopted.
It is generally accepted that the yþL light chain y+LAT1 is
the subunit expressed in absorbing epithelia, while the alter-
native isoform y+LAT2 would be preferentially expressed in
non-epithelial tissues [4]. However, it is known that y+LAT1
also is expressed in non-epithelial cells, such as human ﬁbro-
blasts [16], human endothelial cells [13], and leukocytes
[11,12,15]. This contribution not only demonstrates that
SLC7A7/y+LAT1 is clearly expressed by human monocytes
but also shows the stimulation of its expression by IFNc, a
thus far unknown eﬀect of the cytokine. Although no previous
report had indicated SLC7A7 as a target of IFNc, Mykkanen
et al. [17] have identiﬁed in the 5
0
regulatory region of the gene
several putative transcription factor binding sequences, such as
NFAT, that could be involved in IFNc signal transduction.
Mutations of SLC7A7 gene cause the autosomal recessive
condition lysinuric protein intolerance, LPI [18]. LPI is char-
acterized by selective CAA loss in the urine associated with
several extra-renal alterations, such as a severe alveolar pro-teinosis, suggestive for the involvement of cells of monocyte–
macrophage lineage. The clear-cut expression of SLC7A7/
y+LAT1 in human monocytes and its induction by IFNc
strengthen the possibility that these cells are a phenotypic
target of LPI-associated mutations and prompt further inves-
tigations of this issue.
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